FUDR

FUDR, also known as Floxuridine, is a chemotherapeutic agent used primarily in the treatment of certain cancers. It belongs to the class of drugs known as antimetabolites, which interfere with DNA and RNA synthesis to inhibit cell division and growth. FUDR is structurally similar to the naturally occurring pyrimidine nucleosides and functions as a thymidylate synthase inhibitor, disrupting thymidine production essential for DNA replication.

FUDR is most frequently administered via intra-arterial infusion, particularly for metastatic liver tumors, owing to its high hepatic extraction rate. It can also be given systemically or as a topical agent in certain treatments. The drug’s localized delivery allows for high concentrations at tumor sites while minimizing systemic toxicity.

Common side effects of FUDR include gastrointestinal disturbances, such as nausea, vomiting, and diarrhea, along with hematological effects like leukopenia and thrombocytopenia. Its use requires careful monitoring of blood counts and liver function due to potential toxicity.

FUDR’s pharmacokinetics involve rapid hepatic metabolism to inactive compounds, which facilitates its targeted use in liver-related malignancies. It has been utilized in combination with other chemotherapeutic agents and as part of regional therapy protocols for advanced cancers.

Research continues into its wider applications, including potential uses in preoperative therapy and locoregional treatment regimens. As a potent chemotherapeutic, FUDR plays a significant role in cancer management, especially in cases where targeted, regional treatment approaches are advantageous.